Tuberculosis (TB)-associated immune reconstitution inflammatory syndrome in TB-HIV co-infected patients in Malaysia: Prevalence, risk factors, and treatment outcomes

Sexual Health

Volumn 11, Issue 6, 2014, Pages 532-539

  Tan, Hong Yien ^a   Yong, Yean Kong ^a   Lim, Sin How ^a   Ponnampalavanar, Sasheela ^a,b   Omar, Sharifah F S ^a,b   Pang, Yong Kek ^a,b   Kamarulzaman, Adeeba ^a,b   Price, Patricia ^f   Crowe, Suzanne M ^c,d,e   French, Martyn A ^f,g  

^a UNIVERSITY OF MALAYA   (Malaysia)

^b UNIVERSITY MALAYA MEDICAL CENTRE   (Malaysia)

^c MACFARLANE BURNET INSTITUTE FOR MEDICAL RESEARCH AND PUBLIC HEALTH   (Australia)

^d ALFRED HOSPITAL   (Australia)

^e MONASH UNIVERSITY   (Australia)

^f UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^g ROYAL PERTH HOSPITAL   (Australia)

Author keywords

antiretroviral therapy; antituberculosis treatment.

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; C REACTIVE PROTEIN; ETHAMBUTOL; HEMOGLOBIN; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; VIRUS RNA;

ADULT; ANTIBIOTIC THERAPY; ANTIVIRAL THERAPY; ARTICLE; BACTERIAL LOAD; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CENTRAL NERVOUS SYSTEM TUBERCULOSIS; COHORT ANALYSIS; DISEASE ASSOCIATION; DRUG TREATMENT FAILURE; ENDEMIC DISEASE; EXTRAPULMONARY TUBERCULOSIS; FEMALE; HEMOGLOBIN BLOOD LEVEL; HIGH RISK PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; INCIDENCE; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALAYSIA; MALE; MILIARY TUBERCULOSIS; MIXED INFECTION; MORTALITY; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PATHOGEN CLEARANCE; PREVALENCE; RETROSPECTIVE STUDY; RISK FACTOR; SPUTUM CULTURE; SURVIVAL; TREATMENT DURATION; TREATMENT OUTCOME; TUBERCULIN TEST; TUBERCULOSIS; TUBERCULOUS LYMPHADENITIS; VIRUS LOAD;

EID: 84914173426     PISSN: 14485028     EISSN: 14498987     Source Type: Journal    
DOI: 10.1071/SH14093     Document Type: Article

References (35)

1. World Health Organization (WHO). Global tuberculosis report. Available online at: http://www.who.int/tb/publications/global-report/en/[verified 26 September 2013
2. World Health Organization (WHO). Tuberculosis country profiles. Malaysia. Available at: www.who.int/tb/data [verified 26 September 2013
3. French MA. HIV/AIDS: immune reconstitution inflammatory syndrome: a reappraisal. Clin Infect Dis 2009; 48: 101-7. doi:10.1086/595006
4. Malaysia Health Technology Assessment Section (MaHTAS) MDD, Ministry of Health Malaysia. Clinical practice guidelines. Management of tuberculosis. Putrajaya, Malaysia: MaHTAS; 2012
5. World Health Organization (WHO). Guidelines for treatment of tuberculosis, 4th edn. Geneva: WHO; 2010
6. Meintjes G, Lawn SD, Scano F, Maartens G, French MA, Worodria W, et al. Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect Dis 2008; 8: 516-23. doi:10.1016/S1473-3099(08)70184-1
7. Haddow LJ, Easterbrook PJ, Mosam A, Khanyile NG, Parboosing R, Moodley P, et al. Defining immune reconstitution inflammatory syndrome: evaluation of expert opinion versus 2 case definitions in a South African cohort. Clin Infect Dis 2009; 49: 1424-32. doi:10.1086/630208
8. Lawn SD, Wilkinson RJ, Lipman MC, Wood R. Immune reconstitution and unmasking of tuberculosis during antiretroviral therapy. Am J Respir Crit Care Med 2008; 177: 680-5. doi:10.1164/rccm.200709-1311PP
9. Breton G, Duval X, Estellat C, Poaletti X, Bonnet D, Mvondo Mvondo D, et al. Determinants of immune reconstitution inflammatory syndrome in HIV type 1-infected patients with tuberculosis after initiation of antiretroviral therapy. Clin Infect Dis 2004; 39: 1709-12. doi:10.1086/425742
10. Narita M, Ashkin D, Hollender ES, Pitchenik AE. Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS. Am J Respir Crit Care Med 1998; 158: 157-61. doi:10.1164/ajrccm.158.1.9712001
11. Breen RA, Smith CJ, Bettinson H, Dart S, Bannister B, Johnson MA, et al. Paradoxical reactions during tuberculosis treatment in patients with and without HIV co-infection. Thorax 2004; 59: 704-7. doi:10.1136/thx.2003.019224
12. Michailidis C, Pozniak AL, Mandalia S, Basnayake S, Nelson MR, Gazzard BG. Clinical characteristics of IRIS syndrome in patients with HIV and tuberculosis. Antivir Ther 2005; 10: 417-22
13. Lawn SD, Myer L, Bekker LG, Wood R. Tuberculosis-associated immune reconstitution disease: incidence, risk factors and impact in an antiretroviral treatment service in South Africa. AIDS 2007; 21: 335-41. doi:10.1097/QAD.0b013e328011efac
14. De D, Sarkar RN, Phaujdar S, Bhattacharyya K, Pal HK. Incidence and risk factors of immune reconstitution inflammatory syndrome in HIV-TB coinfected patients. Braz J Infect Dis 2011; 15: 553-9. doi:10.1016/S1413-8670(11)70250-1
15. Serra FC, Hadad D, Orofino RL, Marinho F, Lourenco C, Morgado M, et al. Immune reconstitution syndrome in patients treated for HIV and tuberculosis in Rio De Janeiro. Braz J Infect Dis 2007; 11: 462-5. doi:10.1590/S1413-86702007000500004
16. Agarwal U, Kumar A, Behera D, French MA, Price P. Tuberculosis associated immune reconstitution inflammatory syndrome in patients infected with HIV: meningitis a potentially life threatening manifestation. AIDS Res Ther 2012; 9: 17. doi:10.1186/1742-6405-9- 17
17. UmphonsathienW, Sungkanuparph S. Early initiation of antiretroviral therapy in HIV/Tuberculosis co-infection and immune reconstitution inflammatory syndrome. J Infect Dis Antimicrob Agents 2011; 28: 15-23
18. Manosuthi W, Kiertiburanakul S, Phoorisri T, Sungkanuparph S. Immune reconstitution inflammatory syndrome of tuberculosis among HIV-infected patients receiving antituberculous and antiretroviral therapy. J Infect 2006; 53: 357-63. doi:10.1016/j.jinf. 2006.01.002
19. Aramaki M, Silachamroon U, Desakorn V, Maek-A-nantawat W, Waiwaruwut J, Jutiwarakun K, et al. Immune reconstitution inflammatory syndrome in adult human immunodeficiency virusinfected patients in Thailand. Southeast Asian J Trop Med Public Health 2010; 41: 138-45. doi:20578492
20. Baalwa J, Mayanja-Kizza H, Kamya MR, John L, Kambugu A, Colebunders R. Worsening and unmasking of tuberculosis in HIV-1 infected patients after initiating highly active anti-retroviral therapy in Uganda. Afr Health Sci 2008; 8: 190-5
21. Chang CC, Crane M, Zhou J, Mina M, Post JJ, Cameron BA, et al. HIV and co-infections. Immunol Rev 2013; 254: 114-42. doi:10.1111/imr.12063
22. Oliver BG, Elliott JH, Price P, Phillips M, Saphonn V, Vun MC, et al. Mediators of innate and adaptive immune responses differentially affect immune restoration disease associated with Mycobacterium tuberculosis in HIV patients beginning antiretroviral therapy. J Infect Dis 2010; 202: 1728-37. doi:10.1086/657082
23. Vignesh R, Kumarasamy N, Lim A, Solomon S, Murugavel KG, Balakrishnan P, et al. TB-IRIS after initiation of antiretroviral therapy is associated with expansion of pre-existent Th1 responses against Mycobacterium tuberculosis antigens. J Acquir Immune Defic Syndr 2013; 64: 241-8. doi:10.1097/QAI.0b013e31829f6df2
24. Elliott JH, Vohith K, Saramony S, Savuth C, Dara C, Sarim C, et al. Immunopathogenesis and diagnosis of tuberculosis and tuberculosisassociated immune reconstitution inflammatory syndrome during early antiretroviral therapy. J Infect Dis 2009; 200: 1736-45. doi:10.1086/644784
25. Oliver BG, Elliott JH, Price P, Phillips M, Cooper DA, French MA. Tuberculosis after commencing antiretroviral therapy for HIV infection is associated with elevated CXCL9 and CXCL10 responses to Mycobacterium tuberculosis antigens. J Acquir Immune Defic Syndr 2012; 61: 287-92. doi:10.1097/QAI.0b013e 31826445ef
26. Martin-Blondel G, Mars LT, Liblau RS. Pathogenesis of the immune reconstitution inflammatory syndrome in HIV-infected patients. Curr Opin Infect Dis 2012; 25: 312-20. doi:10.1097/QCO.0b013e3283 52b664
27. Narendran G, Andrade BB, Porter BO, Chandrasekhar C, Venkatesan P, Menon PA, et al. Paradoxical tuberculosis immune reconstitution inflammatory syndrome (TB-IRIS) in HIV patients with culture confirmed pulmonary tuberculosis in India and the potential role of IL-6 in prediction. PLoS ONE 2013; 8: e63541. doi:10.1371/journal. pone.0063541
28. Manabe YC, Kesavan AK, Lopez-Molina J, Hatem CL, Brooks M, Fujiwara R, et al. The aerosol rabbit model of TB latency, reactivation and immune reconstitution inflammatory syndrome. Tuberculosis (Edinb) 2008; 88: 187-96. doi:10.1016/j.tube.2007.10.006
29. Conesa-Botella A, Loembe MM, Manabe YC, Worodria W, Mazakpwe D, Luzinda K, et al. Urinary lipoarabinomannan as predictor for the tuberculosis immune reconstitution inflammatory syndrome. J Acquir Immune Defic Syndr 2011; 58: 463-8. doi:10.1097/QAI.0b013e31823801de
30. Abdool Karim SS, Naidoo K, Grobler A, Padayatchi N, Baxter C, Gray A, et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med 2010; 362: 697-706. doi:10.1056/NEJMoa0905848
31. Gupta P, Vijayan VK, Bansal SK. Changes in protein profile of erythrocyte membrane in bronchial asthma. J Asthma 2012; 49: 129-33. doi:10.3109/02770903.2011.649873
32. Manosuthi W, Mankatitham W, Lueangniyomkul A, Thongyen S, Likanonsakul S, Suwanvattana P, et al. TIME Study Team Time to initiate antiretroviral therapy between 4 weeks and 12 weeks of tuberculosis treatment in HIV-infected patients: results from the TIME study. J Acquir Immune Defic Syndr 2012; 60: 377-83. doi:10.1097/QAI.0b013e31825b5e06
33. Koenig SP, Riviere C, Leger P, Joseph P, Severe P, Parker K, et al. High mortality among patients with AIDS who received a diagnosis of tuberculosis in the first 3 months of antiretroviral therapy. Clin Infect Dis 2009; 48: 829-31. doi:10.1086/597098
34. French MA. Immune reconstitution inflammatory syndrome: immune restoration disease 20 years on. Med J Aust 2012; 196: 318-21. doi:10.5694/mja12.10089
35. Kumarasamy N, Venkatesh KK, Vignesh R, Devaleenal B, Poongulali S, Yepthomi T, et al. Clinical outcomes among HIV/tuberculosiscoinfected patients developing immune reconstitution inflammatory syndrome after HAART initiation in South India. J Int Assoc Provid AIDS Care. 2013; 12: 28-31. doi:23011868